Physician profile
Arshed Malik
NPI 1487659595
$6,725.89
in general payments reported to CMS, 2019-2025
33 companies · $616 in 2025
The $616 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $447 · 2021: $1,060 · 2022: $1,430 · 2023: $1,204 · 2024: $777 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.06 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,201.74 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $884.74 | 2019-2025 | |
| Pfizer INC. | $874.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $635.48 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.46 | 2019-2025 | Jardiance |
| Amgen INC. | $347.94 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $283.64 | 2019-2024 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $279.64 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $231.97 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $199.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $198.62 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Esperion Therapeutics, INC. | $179.61 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $166.24 | 2019-2025 | Wainua, Farxiga |
| Biosense Webster, INC. | $136.76 | 2023-2025 | Carto 3 |
| Bayer Healthcare Pharmaceuticals INC. | $115.14 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $88.08 | 2022-2024 | Cardiomems, Jot Dx |
| Abiomed | $70.13 | 2019-2025 | |
| Atricure, INC. | $60.33 | 2021-2024 | |
| Shockwave Medical, INC | $54.81 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $42.20 | 2025 | Selectsecure |
| Regeneron Healthcare Solutions, INC. | $38.56 | 2019 | |
| Terumo Medical Corporation | $34.25 | 2020-2024 | Glidewire |
| W. L. Gore & Associates, INC. | $32.25 | 2023 | Gore Viabahn Vbx Balloon Expandable Endo |
| Ge Healthcare | $31.93 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $30.54 | 2022-2024 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $28.47 | 2019 | |
| Cook Medical LLC | $20.72 | 2025 | Zilver Ptx |
| Chiesi USA, INC. | $20.60 | 2025 | Kengreal |
| Astellas Pharma US INC | $20.00 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.96 | 2019 | |
| Scpharmaceuticals INC. | $16.16 | 2024 | |
| Biotronik INC. | $14.97 | 2022 | |
| Boston Scientific Corporation | $14.02 | 2023 | Ekosonic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshed Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.